Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PRNP | P04156 | 2/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | PTGFR | P43088 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26565406 | 0.82 | PRNP (0.56) | KMT2AMEN1HTTKDM4EMAPT | |
| SCHEMBL19293871 | 0.81 | KDM4E (0.59) | KMT2AMEN1HTTKDM4EMAPT | |
| SCHEMBL3116382 | 0.79 | HTT (0.55) | KMT2AHTTKDM4EMAPTALDH1A1 | |
| SCHEMBL3486575 | 0.78 | KDM4E (0.71) | KMT2AKDM4EMAPTALDH1A1LMNA | |
| SCHEMBL1757804 | 0.77 | MEN1 (0.54) | KMT2AMEN1AVPR1AHTTKDM4E | |
| SCHEMBL14039064 | 0.76 | CSNK2A2 (0.47) | KMT2AKDM4EMAPTALDH1A1LMNA | |
| SCHEMBL15647747 | 0.75 | MEN1 (0.53) | KMT2AMEN1AVPR1AHTTKDM4E | |
| SCHEMBL182940 | 0.75 | L3MBTL1 (0.51) | KMT2AMEN1HTTKDM4EMAPT | |
| SCHEMBL18089101 | 0.75 | DHODH (0.68) | KMT2AMEN1AVPR1APTGFRDHODH | |
| SCHEMBL25929656 | 0.73 | MAPT (0.46) | KMT2AMEN1HTTKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322650-B1 | FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-7196094-B2 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-20030207887-A1 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-06 | — | — | US | disclosed |
| EP-1322650-A2 | FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002024686-A2 | FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207887-A1 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives | FNTA, FNTB, RCE1 | KMT2A 2337/4885MEN1 1318/4885AVPR1A 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.